Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963019 | 0.89 | TP53 (0.37) | TP53KMT2AHPGD | |
| SCHEMBL5115230 | 0.87 | MTNR1A (0.39) | TP53MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL966068 | 0.87 | SHMT2 (0.38) | TP53MTNR1AMTNR1B | |
| SCHEMBL963219 | 0.87 | MAPT (0.35) | TP53HPGD | |
| SCHEMBL961699 | 0.84 | CYP2C9 (0.34) | TP53 | |
| SCHEMBL964880 | 0.84 | TP53 (0.37) | TP53KMT2AHPGD | |
| SCHEMBL966058 | 0.84 | TP53 (0.38) | TP53KMT2A | |
| SCHEMBL963241 | 0.81 | ALDH1A1 (0.36) | TP53KMT2AHPGD | |
| SCHEMBL962203 | 0.80 | MTNR1A (0.35) | TP53MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL966425 | 0.80 | MTNR1A (0.37) | MTNR1AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | TP53 2149/4885MTNR1A 310/4885MTNR1B 243/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | TP53 1057/4885MTNR1A 69/4885MTNR1B 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.